Literature DB >> 1752787

Fluctuations in tumor blood flow under normotension and the effect of angiotensin II-induced hypertension.

K Hori1, M Suzuki, S Tanda, S Saito, M Shinozaki, Q H Zhang.   

Abstract

To elucidate the significance of angiotensin II (AII)-induced hypertension chemotherapy, changes of tissue blood flow both in normal subcutis and in tumors (AH109A, LY80) were measured with the hydrogen gas clearance method. A newly-developed anesthetic machine was used to keep the animals' condition constant. Tissue blood flow in normal subcutis and tumors always fluctuated with time under normotension. The nature and the rate of fluctuation in tumor blood flow were almost identical in two different types of tumors. However, the fluctuation of blood flow in tumor and that in normal subcutis were almost always inversely related when blood flows in these different tissues were measured simultaneously, i.e., when tissue blood flow in normal subcutis decreased, tumor blood flow increased, and vice versa. The findings supported the idea that the connection mode between the tumor vascular bed and normal vascular bed is a parallel circuit. Vascular resistance in the normal vascular bed under AII-induced hypertension seemed to be greater than that under normotension, because the AII-increased tumor blood flow always exceeded the maximum tumor blood flow under normotension. Due to the fluctuations of tumor blood flow, no-flow or low-flow areas, resistant to delivery of anti-cancer drugs, moved sporadically within the tumor under the normotensive condition. However, good conditions for drug delivery to tumor tissue were induced by AII-induced hypertension.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1752787      PMCID: PMC5918320          DOI: 10.1111/j.1349-7006.1991.tb01797.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  20 in total

1.  [Development of the angioarchitecture and microcirculatory characteristics in rat tumor].

Authors:  K Hori; M Suzuki; S Saito; S Tanda
Journal:  Gan To Kagaku Ryoho       Date:  1990-03

2.  A repeating modular organization of the microcirculation of cat mesentery.

Authors:  W G Frasher; H Wayland
Journal:  Microvasc Res       Date:  1972-01       Impact factor: 3.514

3.  Evidence for acutely hypoxic cells in mouse tumours, and a possible mechanism of reoxygenation.

Authors:  J M Brown
Journal:  Br J Radiol       Date:  1979-08       Impact factor: 3.039

4.  Anaesthetics in the study of the microcirculation of tumours: pitfalls and uses.

Authors:  G D Zanelli; J F Fowler
Journal:  Bibl Anat       Date:  1977

5.  [The effect of induced hypertension chemotherapy using angiotensin II human in patients with advanced gastric carcinoma--a histopathological evaluation on the excised stomachs].

Authors:  M Nakamura; T Takahashi; H Sato; A Wakui; M Hoshi
Journal:  Gan To Kagaku Ryoho       Date:  1991-04

6.  Abnormal response of tumor vasculature to vasoactive drugs.

Authors:  R C Chan; C F Babbs; R J Vetter; C H Lamar
Journal:  J Natl Cancer Inst       Date:  1984-01       Impact factor: 13.506

7.  Functional characterization of the microcirculation in tumors.

Authors:  M Suzuki; K Hori; I Abe; S Saito; H Sato
Journal:  Cancer Metastasis Rev       Date:  1984       Impact factor: 9.264

Review 8.  Chemical modification of tumour blood flow.

Authors:  R L Jirtle
Journal:  Int J Hyperthermia       Date:  1988 Jul-Aug       Impact factor: 3.914

9.  A new approach to cancer chemotherapy: selective enhancement of tumor blood flow with angiotensin II.

Authors:  M Suzuki; K Hori; I Abe; S Saito; H Sato
Journal:  J Natl Cancer Inst       Date:  1981-09       Impact factor: 13.506

10.  Characterization of heterogeneous distribution of tumor blood flow in the rat.

Authors:  K Hori; M Suzuki; S Tanda; S Saito
Journal:  Jpn J Cancer Res       Date:  1991-01
View more
  18 in total

Review 1.  Tumor targeting via EPR: Strategies to enhance patient responses.

Authors:  Susanne K Golombek; Jan-Niklas May; Benjamin Theek; Lia Appold; Natascha Drude; Fabian Kiessling; Twan Lammers
Journal:  Adv Drug Deliv Rev       Date:  2018-07-19       Impact factor: 15.470

2.  Angiotensin II (AII) induced hypertension chemotherapy (IHC) for unresectable gastric cancer: with reference to resection after down staging.

Authors:  H Sato; K Sugiyama; M Hoshi; M Urushiyama; K Ishizuka
Journal:  World J Surg       Date:  1995 Nov-Dec       Impact factor: 3.352

Review 3.  Macromolecular therapeutics: advantages and prospects with special emphasis on solid tumour targeting.

Authors:  Khaled Greish; Jun Fang; Takao Inutsuka; Akinori Nagamitsu; Hiroshi Maeda
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 4.  Pharmacological and physical vessel modulation strategies to improve EPR-mediated drug targeting to tumors.

Authors:  Tarun Ojha; Vertika Pathak; Yang Shi; Wim E Hennink; Chrit T W Moonen; Gert Storm; Fabian Kiessling; Twan Lammers
Journal:  Adv Drug Deliv Rev       Date:  2017-07-08       Impact factor: 15.470

Review 5.  Vascular permeability in cancer and infection as related to macromolecular drug delivery, with emphasis on the EPR effect for tumor-selective drug targeting.

Authors:  Hiroshi Maeda
Journal:  Proc Jpn Acad Ser B Phys Biol Sci       Date:  2012       Impact factor: 3.493

6.  Modification of tumour blood flow using the hypertensive agent, angiotensin II.

Authors:  G M Tozer; K M Shaffi
Journal:  Br J Cancer       Date:  1993-05       Impact factor: 7.640

7.  A novel combretastatin A-4 derivative, AC7700, strongly stanches tumour blood flow and inhibits growth of tumours developing in various tissues and organs.

Authors:  K Hori; S Saito; K Kubota
Journal:  Br J Cancer       Date:  2002-05-20       Impact factor: 7.640

8.  Augmentation of tumour delivery of macromolecular drugs with reduced bone marrow delivery by elevating blood pressure.

Authors:  C J Li; Y Miyamoto; Y Kojima; H Maeda
Journal:  Br J Cancer       Date:  1993-05       Impact factor: 7.640

9.  Variation of growth rate of a rat tumour during a light-dark cycle: correlation with circadian fluctuations in tumour blood flow.

Authors:  K Hori; Q H Zhang; H C Li; S Saito
Journal:  Br J Cancer       Date:  1995-06       Impact factor: 7.640

10.  The response of tumour vasculature to angiotensin II revealed by its systemic and local administration to 'tissue-isolated' tumours.

Authors:  G M Tozer; K M Shaffi
Journal:  Br J Cancer       Date:  1995-09       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.